Medicine and Health

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

J. Zhang, Y. Hu, et al.

This groundbreaking research illustrates the creation of non-viral, gene-specific targeted CAR-T cells using CRISPR-Cas9, leading to an impressive 87.5% complete remission rate in patients with aggressive B-cell non-Hodgkin lymphoma. Conducted by a team of experts, the study highlights the innovative use of PD1 integration for enhanced anti-tumor efficacy.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Neutralizing IFNγ Improves Safety without Compromising Efficacy of CAR-T Cell Therapy in B-cell Malignancies

S. Manni, F. D. Bufalo, et al.

Medicine and Health

Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial

C. Moritz, E. C. Field-fote, et al.

Medicine and Health

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML

D. Nixdorf, M. Sponheimer, et al.

Medicine and Health

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

C. E. Brown, J. C. Hibbard, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny